QualityStocks'  Instablog

Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • Arch Therapeutics, Inc. (ARTH) Reports Directors, Leadership Appointments 4 comments
    Jul 3, 2013 10:57 AM

    Arch Therapeutics, a life science company and developer of AC5™ for controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, has named Dr. Avtar Dhillon as board chair, Dr. Arthur Rosenthal as director, and Dr. Terrence W. Norchi as president and CEO.

    Dr. Dhillon has experience in company building, financing, and licensing with large industry partners, has served as the chairman of ARTH's board of directors since April 2013, and has been on the board of directors of Arch Biosurgery, Inc. (NYSE:ABS) since May 2011.

    His previous employment includes the roles of president, chairman and CEO of Inovio Pharmaceuticals where he led the successful turnaround of the company through restructuring, acquisition of technology from several European and North American companies, and a merger with VGX Pharmaceuticals. Dr. Dhillon also led several successful financings for Inovio and concluded numerous licensing deals that included global giants Merck and Wyeth (now Pfizer).

    Dr. Rosenthal was appointed a director of ARTH upon the completion of the company's previously announced merger, and had been the chairman of the board of ABS since April 2011. He has 40 years of experience in senior research and product development through executive roles for medical technology companies. He has also directed commercialization efforts for hundreds of novel medical products. Dr. Rosenthal was formerly chief scientific officer at Boston Scientific and vice president of Research and Development at Johnson and Johnson Medical Products, Inc.

    Dr. Norchi, on April 23, 2013, began his role with ARTH as president, CEO, and a director. Dr. Norchi has also served as the president, CEO, and director of ABS since co-founding it in 2006. He previously served as a portfolio manager and pharmaceutical analyst at Putnam Investments; senior global biotech and international pharmaceutical equity analyst at Citigroup Asset Management; and a sell-side analyst covering non-U.S. pharmaceutical equities at Sanford C. Bernstein in New York City.

    For more information, visit archtherapeutics.com

    Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (4)
Track new comments
  • Alan Brochstein, CFA
    , contributor
    Comments (7950) | Send Message
    Total scam:http://bit.ly/187agK6
    10 Jul 2013, 02:08 PM Reply Like
  • arisberna
    , contributor
    Comments (111) | Send Message
    Hi Alan,


    I am really skeptic about this stock too.


    However I would like to understand one thing. How is it possible that such Respected Management and Advisory Board will be put on this company if its a scam? Should this people lose reputation if they associate themselves with a scam?


    Thank you,
    12 Jul 2013, 02:58 AM Reply Like
  • Alan Brochstein, CFA
    , contributor
    Comments (7950) | Send Message
    That is the interesting part. Check out the record of Dhillon - not so great.
    12 Jul 2013, 06:04 AM Reply Like
  • arisberna
    , contributor
    Comments (111) | Send Message
    thanks Alan, yep that was correct!
    17 Jul 2013, 04:28 AM Reply Like
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.